Venarus^® (Tablets) Instructions for Use

ATC Code

C05CA53 (Diosmin in combination with other drugs)

Active Substances

Diosmin (Rec.INN)

Hesperidin (Grouping Name)

Clinical-Pharmacological Group

Venotonic drug

Pharmacotherapeutic Group

Venotonic and venoprotective agent

Pharmacological Action

Venarus^® exerts an angioprotective and venotonic action.

It reduces venous distensibility, increases venous tone, and reduces venous stasis; it decreases capillary permeability and fragility and increases capillary resistance; it improves microcirculation and lymphatic drainage.

With systematic use, it reduces the severity of clinical manifestations of chronic venous insufficiency of the lower limbs of organic and functional nature.

The optimal dose-effect ratio is observed at a dose of 1000 mg/day.

Pharmacokinetics

The main route of excretion of the drug is through the intestine.

On average, about 14% of the administered dose is excreted via the kidneys.

The T_1/2 is 11 hours.

The drug Venarus^® undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Indications

Venarus^® is indicated for the therapy of symptoms of chronic diseases (elimination and relief of symptoms).

Therapy of symptoms of venolymphatic insufficiency

• Cramps in the lower limbs;
• Sensation of heaviness and distension in the legs;
• Pain;
• “tired” legs.

Therapy of manifestations of venolymphatic insufficiency

• Edema of the lower limbs;
• Trophic changes of the skin and subcutaneous tissue;
• Venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

ICD codes

Dosage Regimen

Tablets

Orally.

The recommended dose for venolymphatic insufficiency is 1 tablet/day, preferably in the morning, with meals.

The score on the tablet is intended solely for dividing to facilitate swallowing.

The duration of the treatment course can be several months (up to 12 months).

In case of recurrence of symptoms, on the doctor’s recommendation, the treatment course can be repeated.

The recommended dose for acute hemorrhoids is 3 tablets/day (1 tablet in the morning, afternoon, and evening) for 4 days, then 2 tablets/day (1 tablet in the morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1 tablet/day.

Adverse Reactions

The frequency of adverse reactions is presented as follows: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000), and very rare (<1/10,000).

Adverse reactions, the frequency of which cannot be estimated from the available data, are designated as “frequency unknown”.

Nervous system disorders rare – dizziness, headache, general malaise.

Gastrointestinal disorders common – diarrhea, dyspepsia, nausea, vomiting; uncommon – colitis; frequency unknown – abdominal pain.

Skin and subcutaneous tissue disorders rare – rash, pruritus, urticaria; frequency unknown – isolated edema of the face, lips, eyelids, in exceptional cases angioedema.

If any of the adverse reactions listed in the instructions worsen, or the patient notices any other adverse reactions not listed in the instructions, they should inform their doctor.

Contraindications

• Hypersensitivity to the active substances or to any of the excipients included in the drug;
• Use of the drug is not recommended for women during breastfeeding.

Use in Pregnancy and Lactation

Pregnancy

Experiments on animals have not revealed teratogenic effects.

To date, there have been no reports of any adverse effects when the drug was used by pregnant women.

Breastfeeding period

Due to the lack of data regarding the excretion of the drug in breast milk, the use of the drug is not recommended for women during breastfeeding.

Effect on the reproductive system

Reproductive toxicity studies did not show any effect on reproductive function in rats of both sexes.

Special Precautions

Before starting to take Venarus^®, it is recommended to consult a doctor.

In case of exacerbation of hemorrhoids, the prescription of Venarus^® does not replace specific treatment for other anal disorders.

The duration of treatment should not exceed the terms specified in the “Dosage Regimen” section.

If the symptoms do not disappear after the recommended course of therapy, a proctologist should be consulted to select further therapy.

In the presence of venous circulation disorders, the maximum therapeutic effect is achieved by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid prolonged exposure to the sun, prolonged standing, and weight reduction is recommended in case of excess body weight.

Walking and, in some cases, wearing special stockings, promotes better blood circulation.

The patient should immediately consult a doctor if their condition worsens or does not improve during treatment.

Effect on ability to drive vehicles and operate machinery

No effect.

Overdose

No cases of overdose have been reported.

In case of drug overdose, the patient should immediately seek medical help.

Drug Interactions

None noted.

The treating physician should be informed about all medications being taken.

Storage Conditions

The drug should be stored at a temperature not exceeding 25°C (77°F).

Shelf Life

The shelf life is 3 years. Do not use after the expiration date printed on the package.

Dispensing Status

The drug is available without a prescription.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.